| Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10269), 99-111, 2021 | 5440 | 2021 |
| PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression CL Day, DE Kaufmann, P Kiepiela, JA Brown, ES Moodley, S Reddy, ... Nature 443 (7109), 350-354, 2006 | 3285 | 2006 |
| Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478, 2020 | 2831 | 2020 |
| The human cell atlas A Regev, SA Teichmann, ES Lander, I Amit, C Benoist, E Birney, ... elife 6, e27041, 2017 | 2091 | 2017 |
| Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections V Appay, PR Dunbar, M Callan, P Klenerman, GMA Gillespie, L Papagno, ... Nature medicine 8 (4), 379-385, 2002 | 1957 | 2002 |
| Guidelines for the use of flow cytometry and cell sorting in immunological studies A Cossarizza, HD Chang, A Radbruch, A Acs, D Adam, S Adam‐Klages, ... European journal of immunology 49 (10), 1457-1973, 2019 | 1801 | 2019 |
| Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial MN Ramasamy, AM Minassian, KJ Ewer, AL Flaxman, PM Folegatti, ... The Lancet 396 (10267), 1979-1993, 2020 | 1707 | 2020 |
| Analysis of successful immune responses in persons infected with hepatitis C virus F Lechner, DKH Wong, PR Dunbar, R Chapman, RT Chung, ... The Journal of experimental medicine 191 (9), 1499-1512, 2000 | 1637 | 2000 |
| Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four … M Voysey, SAC Clemens, SA Madhi, LY Weckx, PM Folegatti, PK Aley, ... The Lancet 397 (10277), 881-891, 2021 | 1364 | 2021 |
| Genetic mechanisms of critical illness in COVID-19 E Pairo-Castineira, S Clohisey, L Klaric, AD Bretherick, K Rawlik, D Pasko, ... Nature 591 (7848), 92-98, 2021 | 1363 | 2021 |
| Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Y Peng, AJ Mentzer, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai, ... Nature immunology 21 (11), 1336-1345, 2020 | 1224 | 2020 |
| Evidence of escape of SARS-CoV-2 variant B. 1.351 from natural and vaccine-induced sera D Zhou, W Dejnirattisai, P Supasa, C Liu, AJ Mentzer, HM Ginn, Y Zhao, ... Cell 184 (9), 2348-2361. e6, 2021 | 1150 | 2021 |
| Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA P Kiepiela, AJ Leslie, I Honeyborne, D Ramduth, C Thobakgale, S Chetty, ... Nature 432 (7018), 769-775, 2004 | 1009 | 2004 |
| SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses W Dejnirattisai, J Huo, D Zhou, J Zahradník, P Supasa, C Liu, ... Cell 185 (3), 467-484. e15, 2022 | 954 | 2022 |
| Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection DA Price, PJR Goulder, P Klenerman, AK Sewell, PJ Easterbrook, ... Proceedings of the National Academy of Sciences 94 (5), 1890-1895, 1997 | 915 | 1997 |
| COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study VJ Hall, S Foulkes, A Saei, N Andrews, B Oguti, A Charlett, E Wellington, ... The Lancet 397 (10286), 1725-1735, 2021 | 788 | 2021 |
| Reduced neutralization of SARS-CoV-2 B. 1.617 by vaccine and convalescent serum C Liu, HM Ginn, W Dejnirattisai, P Supasa, B Wang, A Tuekprakhon, ... Cell 184 (16), 4220-4236. e13, 2021 | 767 | 2021 |
| Mapping the human genetic architecture of COVID-19 Writing group Writing group leaders Pathak Gita A. 6 Andrews Shea J. 7 Kanai ... Nature 600 (7889), 472-477, 2021 | 756 | 2021 |
| Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor–neutralizing therapy in patients with inflammatory bowel disease NR West, AN Hegazy, BMJ Owens, SJ Bullers, B Linggi, S Buonocore, ... Nature medicine 23 (5), 579-589, 2017 | 698 | 2017 |
| SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN) VJ Hall, S Foulkes, A Charlett, A Atti, EJM Monk, R Simmons, E Wellington, ... The Lancet 397 (10283), 1459-1469, 2021 | 691 | 2021 |
